España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Neurocrine Biosciences
NBIX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$120.69
4.58
3.94%
At close: -
$120.69
0.00
0.00%
After Hours: 4:02 PM EDT
Get Report
Comment
Neurocrine Biosciences (NBIX) Forecast
News
Earnings
Neurocrine Biosciences (NBIX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Neurocrine Biosciences (NASDAQ:NBIX) Stock
Neurocrine Biosciences Stock (NASDAQ: NBIX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 21, 2025
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Neurocrine Biosciences Authorizes $500M Share...
Benzinga Newsdesk
Monday, February 10, 2025
Neurocrine Biosciences shares are trading low...
Benzinga Newsdesk
Guggenheim Maintains Buy on Neurocrine Biosci...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Neurocri...
Benzinga Newsdesk
Sunday, February 09, 2025
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?
Lekha Gupta
Friday, February 07, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
RBC Capital Maintains Sector Perform on Neuro...
Benzinga Newsdesk
Wedbush Maintains Outperform on Neurocrine Bi...
Benzinga Newsdesk
Canaccord Genuity Maintains Buy on Neurocrine...
Benzinga Newsdesk
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Vandana Singh
Neurocrine Biosciences shares are trading low...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Neurocri...
Benzinga Newsdesk
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
B of A Securities Maintains Buy on Neurocrine...
Benzinga Newsdesk
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Thursday, February 06, 2025
Earnings Summary: Neurocrine Biosciences Q4
Benzinga Insights
Neurocrine Biosciences Sees INGREZZA FY25 Net...
Benzinga Newsdesk
Neurocrine Biosciences Q4 2024 Adj EPS $1.69 ...
Benzinga Newsdesk
Earnings Scheduled For February 6, 2025
Benzinga Insights
Tuesday, February 04, 2025
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Benzinga Insights
Morgan Stanley Maintains Overweight on Neuroc...
Benzinga Newsdesk
Thursday, January 30, 2025
UBS Maintains Buy on Neurocrine Biosciences, ...
Benzinga Newsdesk
Tuesday, January 28, 2025
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Vandana Singh
Neurocrine Biosciences Initiates Phase 3 Regi...
Benzinga Newsdesk
Monday, January 27, 2025
Neurocrine Biosciences Amends Agreement With ...
Benzinga Newsdesk
Tuesday, January 21, 2025
Neurocrine Announced Publication Of Supplemen...
Benzinga Newsdesk
Wednesday, January 08, 2025
UBS Maintains Buy on Neurocrine Biosciences, ...
Benzinga Newsdesk
Neurocrine Biosciences Publishes Narrative Re...
Benzinga Newsdesk
Monday, December 23, 2024
Piper Sandler Reiterates Overweight on Neuroc...
Benzinga Newsdesk
Barclays Maintains Overweight on Neurocrine B...
Benzinga Newsdesk
Sunday, December 22, 2024
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Lekha Gupta
Friday, December 20, 2024
What Analysts Are Saying About Neurocrine Biosciences Stock
Benzinga Insights
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Monday, December 16, 2024
Neurocrine Biosciences shares are trading hig...
Benzinga Newsdesk
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Vandana Singh
Wedbush Reiterates Outperform on Neurocrine B...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Reported Friday, Neurocrine Biosciences' CREN...
Benzinga Newsdesk
Tuesday, December 03, 2024
Screening For Black Friday Bargains In The Stock Market
David Pinsen
Wednesday, November 13, 2024
Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences
Benzinga Insights
Tuesday, November 12, 2024
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Vandana Singh
Monday, November 11, 2024
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Thursday, November 07, 2024
Neurocrine Biosciences Unveils KINECT-HD Data...
Benzinga Newsdesk
Monday, November 04, 2024
Neurocrine Biosciences Reveals New INGREZZA D...
Benzinga Newsdesk
Friday, November 01, 2024
HC Wainwright & Co. Reiterates Buy on Neurocr...
Benzinga Newsdesk
Thursday, October 31, 2024
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Wednesday, October 30, 2024
Needham Reiterates Hold on Neurocrine Bioscie...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch